HomeCompareOLK vs JNJ

OLK vs JNJ: Dividend Comparison 2026

OLK yields 7.67% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OLK wins by $13.2K in total portfolio value
10 years
OLK
OLK
● Live price
7.67%
Share price
$26.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.2K
Annual income
$1,246.63
Full OLK calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — OLK vs JNJ

📍 OLK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOLKJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OLK + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OLK pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OLK
Annual income on $10K today (after 15% tax)
$651.84/yr
After 10yr DRIP, annual income (after tax)
$1,059.64/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, OLK beats the other by $356.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OLK + JNJ for your $10,000?

OLK: 50%JNJ: 50%
100% JNJ50/50100% OLK
Portfolio after 10yr
$26.6K
Annual income
$1,037.21/yr
Blended yield
3.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

OLK
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Price Target
$21.50
-17.6% upside vs current
Range: $16.00 — $27.00
Altman Z
24.1
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OLK buys
0
JNJ buys
0
No recent congressional trades found for OLK or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOLKJNJ
Forward yield7.67%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$33.2K$20.0K
Annual income after 10y$1,246.63$827.78
Total dividends collected$10.1K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$21.50$228.73

Year-by-year: OLK vs JNJ ($10,000, DRIP)

YearOLK PortfolioOLK Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,467$766.87$10,676$355.77+$791.00OLK
2$13,091$821.83$11,407$389.39+$1.7KOLK
3$14,885$876.88$12,198$426.53+$2.7KOLK
4$16,858$931.77$13,056$467.62+$3.8KOLK
5$19,025$986.29$13,987$513.12+$5.0KOLK
6$21,397$1,040.21$14,998$563.56+$6.4KOLK
7$23,988$1,093.37$16,098$619.52+$7.9KOLK
8$26,813$1,145.58$17,295$681.69+$9.5KOLK
9$29,886$1,196.71$18,599$750.82+$11.3KOLK
10$33,225$1,246.63$20,022$827.78+$13.2KOLK

OLK vs JNJ: Complete Analysis 2026

OLKStock

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

Full OLK Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this OLK vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OLK vs SCHDOLK vs JEPIOLK vs OOLK vs KOOLK vs MAINOLK vs ABBVOLK vs MRKOLK vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.